---
figid: PMC6826966__cancers-11-01591-g002
figlink: /pmc/articles/PMC6826966/figure/cancers-11-01591-f002/
number: F2
caption: 'Mechanism of resistance to arsenic trioxide- all-trans retinoic acid (ATO-ATRA)
  therapy in APL. The resistance to ATRA and ATO may derive from: (i) genetic mutations
  resulting in amino acid substitution in the RARa ligand binding domain (LBD) and
  in the PML-B2 domain of PML-RARa (ii) deregulated pathways like AKT/mTOR, activators
  of MAP kinase pathway and/or other epigenetic controllers or additional gene mutations
  (ei WT1), (iii) FLT3-ITD severely blunts ATRA response, which fails to degrade PML-RARA
  protein whose persistence in the cells confers the APL phenotype with PML nuclear
  body disruption and deactivation of P53 signaling. This type of resistance is overcome
  by ATO (iv) some autophagy regulatory proteins BECN1 and p62/SQSTM1 have been shown
  to play a pro-survival role during ATRA and ATO treatment, (v) alterations in the
  redox system. (vi) Metabolic alterations (vii) High expression of multi drug resistant
  (MDR) proteins, (viii) Microenvironment influences (ix) Presence of X-RARa fusions.'
pmcid: PMC6826966
papertitle: 'Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis,
  Resistance and on Innovative Treatment Strategies.'
reftext: N. I. Noguera, et al. Cancers (Basel). 2019 Oct;11(10):1591.
pmc_ranked_result_index: '5917'
pathway_score: 0.7852397
filename: cancers-11-01591-g002.jpg
figtitle: Mechanism of resistance to arsenic trioxide- all-trans retinoic acid (ATO-ATRA)
  therapy in APL
year: '2019'
organisms: Homo sapiens
ndex: 054c1a3c-df2c-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6826966__cancers-11-01591-g002.html
  '@type': Dataset
  description: 'Mechanism of resistance to arsenic trioxide- all-trans retinoic acid
    (ATO-ATRA) therapy in APL. The resistance to ATRA and ATO may derive from: (i)
    genetic mutations resulting in amino acid substitution in the RARa ligand binding
    domain (LBD) and in the PML-B2 domain of PML-RARa (ii) deregulated pathways like
    AKT/mTOR, activators of MAP kinase pathway and/or other epigenetic controllers
    or additional gene mutations (ei WT1), (iii) FLT3-ITD severely blunts ATRA response,
    which fails to degrade PML-RARA protein whose persistence in the cells confers
    the APL phenotype with PML nuclear body disruption and deactivation of P53 signaling.
    This type of resistance is overcome by ATO (iv) some autophagy regulatory proteins
    BECN1 and p62/SQSTM1 have been shown to play a pro-survival role during ATRA and
    ATO treatment, (v) alterations in the redox system. (vi) Metabolic alterations
    (vii) High expression of multi drug resistant (MDR) proteins, (viii) Microenvironment
    influences (ix) Presence of X-RARa fusions.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT3
  - AKT1
  - AKT2
  - CACNA1E
  - BCOR
  - FLT3
  - MTOR
  - NFKB1
  - TP53
  - ZBTB16
  - PML
  - RARA
  - TNF
  - COX8A
  - GSH
  - THF
  - CH
  - ATO
  - ATRA
  - NBL-RA
  - NBL-RA
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: B2
  symbol: BII
  source: hgnc_alias_symbol
  hgnc_symbol: CACNA1E
  entrez: '777'
- word: BCOR
  symbol: BCOR
  source: hgnc_symbol
  hgnc_symbol: BCOR
  entrez: '54880'
- word: FLT3
  symbol: FLT3
  source: hgnc_symbol
  hgnc_symbol: FLT3
  entrez: '2322'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: P53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: PLZF
  symbol: PLZF
  source: hgnc_alias_symbol
  hgnc_symbol: ZBTB16
  entrez: '7704'
- word: PML,RARa
  symbol: PML
  source: hgnc_symbol
  hgnc_symbol: PML
  entrez: '5371'
- word: RARa
  symbol: RARA
  source: hgnc_symbol
  hgnc_symbol: RARA
  entrez: '5914'
- word: TNF
  symbol: TNF
  source: hgnc_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: viii)
  symbol: VIII
  source: hgnc_alias_symbol
  hgnc_symbol: COX8A
  entrez: '1351'
- word: ZBTB16
  symbol: ZBTB16
  source: hgnc_symbol
  hgnc_symbol: ZBTB16
  entrez: '7704'
chemicals:
- word: GSH
  source: MESH
  identifier: D005978
- word: THF
  source: MESH
  identifier: C006461
- word: CH
  source: MESH
  identifier: C103208
- word: ATO
  source: MESH
  identifier: C553022
- word: ATRA
  source: MESH
  identifier: D014212
- word: NBL-RA
  source: MESH
  identifier: C076888
diseases:
- word: NBL-RA
  source: MESH
  identifier: D001172
figid_alias: PMC6826966__F2
redirect_from: /figures/PMC6826966__F2
figtype: Figure
---
